MTOR and obesity disorder: In a high-fat diet (HFD)-induced obesity mouse model, 8 weeks of empagliflozin administration improved cardiac dysfunction via Sestrin2-mediated AMPK-mammalian target of rapamycin (mTOR) pathways by maintaining the redox stability [104].